



Key Indices Update

Indices	Close	Change (%)
Nifty	25,815.55	עוו.0
Sensex	84,481.81	ע20.09
Midcap	59,592.15	0.347
Smallcap	17,160.20	0.137

Trend Strength Indicator

Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
34	1271/1824

Key Data

Data	Current	Previous
Dow Jones	48,290.8	47,973.5
U.S. Dollar Index	98.44	98.35
Brent Crude (USD/BBL)	59.74	60.55
US 10Y Bond Yield (%)	4.13	4.16
India 10Y Bond Yield (%)	6.59	6.60

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	58902.95	0.04لا
NIFTYAUTO	27304.75	ע 0.67ע
NIFTYENERG	34467.75	لا 0.78
NIFTYFINSR	29747.55	0.237
NIFTYFMCG	54545.55	עוו.0
NIFTYIT	38641.75	1.237
NIFTYMEDIA	1391.35	1.40كا
NIFTYMETAL	10505.15	0.147
NIFTYPHARM	22563.30	0.22צ
NIFTYREALT	867.50	0.017

Dec 19, 2025

Fundamental

Refer Page 02

Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
LEMONTREE	FMCG	159	187	17.5%

*CMP as on December 18

Top News

- + Max Healthcare has approved the acquisition of 100% of Yerawada Properties (YPPL) and plans to invest up to ₹1,020 crore to build a 450-bed super-specialty hospital in Pune. This strategic investment expands Max Healthcare's footprint in a key market and enhances its capacity to offer advanced medical services in western India.
- + MTAR Technologies has won a ₹310 crore order from Megha Engineering for supplying critical equipment to Kaiga nuclear power units 5 and 6. The contract strengthens its nuclear order book and provides long-term revenue visibility through deliveries scheduled up to 2030.

Technical

Refer Page 03-04

- + Nifty traded with a cautious bias and ended flat, extending the ongoing consolidation phase.
- + From a technical perspective, the **Nifty has managed to hold**the crucial support near the previous swing low around 25,700,
 which remains a key level to monitor in the coming session, as a
 breakdown could lead to further correction.
- + On the upside, the short-term moving average, the 20-DEMA, continues to act as an immediate hurdle around 25,950, and a sustained move above this level will be essential for the next leg of the up move.
- Given the prevailing choppiness and absence of strong triggers, stock-specific trading approach remains advisable, with an emphasis on disciplined risk management and controlled position sizing.
- + Stock of the day TECHM





Fundamental

Top News

01

Max Healthcare has approved the acquisition of 100% of Yerawada Properties (YPPL) and plans to invest up to ₹1,020 crore to build a 450-bed super-specialty hospital in Pune. This strategic investment expands Max Healthcare's footprint in a key market and enhances its capacity to offer advanced medical services in western India.

- 02
- MTAR Technologies has won a ₹310 crore order from Megha Engineering for supplying critical equipment to Kaiga nuclear power units 5 and 6. The contract strengthens its nuclear order book and provides long-term revenue visibility through deliveries scheduled up to 2030.
- 03
- Clean Science & Technology has begun commercial production of hydroquinone and catechol at its Dahej, Gujarat facility. These high-value specialty chemicals are used in pharmaceuticals, agrochemicals, and polymers, and the launch strengthens the company's product portfolio, manufacturing scale, and long-term growth prospects.
- 04
- Patel Engineering has signed an MoU with the Government of Arunachal Pradesh to revive and develop the 144 MW Gongri hydropower project, valued around ₹1,700 crore, marking a major renewable energy infrastructure win and strengthening its project pipeline in the Northeast.
- 05

ITI Limited plans to monetise a 91.43-acre land parcel in Bengaluru, valued at about ₹3,473 crore, to repay bank loans and clear pending statutory dues and employee liabilities. The move aims to strengthen the PSU's financial position and reduce debt.

Stock for Investment

Lemon Tree Hotels Ltd

Stock Symbol	LEMONTREE
Sector	Hotel
*CMP (₹)	159
^Target Price (₹)	187
Upside	17.5%

- + Record Quarter Driven by Demand and Pricing: Lemon Tree Hotels, India's largest mid-priced hotel chain, delivered a record Q2FY26 with 8% revenue and 20% PAT growth, driven by stronger ARR and steady travel demand.
- + Short-Term Margin Pressure, Long-Term Upside: EBITDA margins dipped due to heavy renovations and tech investments, but revamped properties are already showing sharp RevPAR gains.
- + Asset-Light Expansion Fuels Scalable Growth: With most rooms already refurbished and more asset-light contracts signed, the portfolio is set for stronger pricing and faster, low-leverage growth.
- + Outlook and Recommendation: Debt reduction, improved credit rating, and strong H2 demand visibility support long-term growth.

 We retain a BUY with a target price of ₹187.

^{*}CMP as on December 18, 2025 ^Time horizon - upto 11 Months





Technical

Critical to hold 25700 for rebound. Stay selective.

NIFTY	S1	S2	RI	R2
25815.55 🛂 3.00 (0.01%)	25700	25600	25950	26050



- + Nifty traded with a cautious bias and ended flat, extending the ongoing consolidation phase.
- + From a technical perspective, Nifty has managed to hold the crucial support near the previous swing low around 25,700, which remains a key level to monitor in the coming session, as a breakdown could lead to further correction.
- On the upside, the short-term moving average, the 20-DEMA, continues to act as an immediate hurdle around 25,950, and a sustained move above this level will be essential for the next leg of the up move.
- Given the prevailing choppiness and absence of strong triggers, stock-specific trading approach remains advisable, with an emphasis on disciplined risk management and controlled position sizing.

BANKNIFTY	S1	S2	RI	R2
58912.85 \(\) 13.90 (0.02%)	58700	58400	59200	59500



- The banking index experienced a highly volatile trading session and ultimately closed sideways with marginal losses.
- + The index opened with a gap-down, recovered sharply, and later declined to settle near flat levels, indicating a strong tussle between bullish and bearish participants.
- + Momentum remained mixed across constituents, with Federal Bank and Axis Bank outperforming, while PNB and HDFC Bank lagged.
- + Technically, immediate resistance is placed near 59,500, with initial support around 58.400.





Technical

Stock of the day	Recom.	CMP (₹)	Range*	SL	Target
ТЕСНМ	BUY	1605.60	1603-1606	1555	1705



- TECHM is displaying a bullish formation, having registered a strong rebound from recent lows and surpassed a prior swing high.
- Prices are sustaining above key short- and medium-term moving averages, indicating a trend reversal. Rising volumes reflect accumulation activity.
- Overall price action suggests strengthening bullish sentiment, and continued stability at current levels may support further upside.
- In alignment with the prevailing trend, long positions may be considered.

' 0	Nume
Momentum Stocks Midcap	MOTILAL
- =	NAM-INE
entur Mido	MAXHEA
ome I	ABSLAMO
Σ	APTLIS

Top 5 F&O Gainers 7

Name	Price	Price %
MOTILALOFS	865.00	3.747
NAM-INDIA	888.30	2.697
MAXHEALTH	1048.00	1.647
ABSLAMC	785.00	1.577
APTUS	282.90	0.72

Name	Price	Price %
HDFCAMC	2725.00	7.237
POLICYBZR	1835.00	3.977
KFINTECH	1070.00	3.75≉
ASHOKLEY	171.45	3.207
INDIGO	5125.00	2.907

ırts	Name	Price	Price %
	APLAPOLLO	1795.10	1.737
Charts	HINDZINC	591.05	2.207
Bullish (ICICIPRULI	646.80	2.597
Bu	OBEROIRLTY	1650.40	2.527
	TCS	3281.20	1.977
	TCS	3281.20	1.977

Name	Price	Price %	-
ICICIPRULI	646.80	2.597	Rang
PHOENIXLTD	1788.10	0.377	ge B
KPITTECH	1160.00	لا0.76	Breako ikdown
EXIDEIND	358.50	لا1.46) 100 €
UNITDSPR	1391.20	لا2.37	

Name	Price	Price %	7
POWERINDIA	18145.00	5.25كا	Top 5
IOC	161.73	3.824	F&O
CUMMINSIND	4376.00	3.03ك	
SUNPHARMA	1746.00	2.62كا	Losers
SAIL	126.95	2.50كا	K

Name	Price	Price %	
ALKEM	5506.00	2.18	Bearish
SIEMENS	3080.00	בופ.ו	
TORNTPOWER	1253.00	1.692	Charts
UNITDSPR	1391.20	ע2.37	rts
UNOMINDA	1221.00	لا2.23	





Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Rajan Gupta	rajan.gupta1@religare.com
Vivek Chandra	vivek.chandra@religare.com
Himanshu Gupta	himanshu.gupta1@religare.com
Vishvajeet Singh	vishvajeet.singh1@religare.com





Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation—Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Ans	Answer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]	-	No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No	
	I/we have received any compensation from the subject company in the past twelve months?		No	
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No	
	I/we have served as an officer, director or employee of the subject company?		No	
	I/we have been engaged in market making activity for the subject company?		No	

Nature of Interest if answer to F(a) above is Yes:	Name(s) with Signature(s) of RA(s)

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results



